18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pathological gambling is a psychiatric disorder and the first recognized behavioral addiction, with similarities to substance use disorders but without the confounding effects of drug-related brain changes. Pathophysiology within the opioid receptor system is increasingly recognized in substance dependence, with higher mu-opioid receptor (MOR) availability reported in alcohol, cocaine and opiate addiction. Impulsivity, a risk factor across the addictions, has also been found to be associated with higher MOR availability. The aim of this study was to characterize baseline MOR availability and endogenous opioid release in pathological gamblers (PG) using [ 11C]carfentanil PET with an oral amphetamine challenge. Fourteen PG and 15 healthy volunteers (HV) underwent two [ 11C]carfentanil PET scans, before and after an oral administration of 0.5 mg/kg of d-amphetamine. The change in [ 11C]carfentanil binding between baseline and post-amphetamine scans (ΔBP ND) was assessed in 10 regions of interest (ROI). MOR availability did not differ between PG and HV groups. As seen previously, oral amphetamine challenge led to significant reductions in [ 11C]carfentanil BP ND in 8/10 ROI in HV. PG demonstrated significant blunting of opioid release compared with HV. PG also showed blunted amphetamine-induced euphoria and alertness compared with HV. Exploratory analysis revealed that impulsivity positively correlated with caudate baseline BP ND in PG only. This study provides the first evidence of blunted endogenous opioid release in PG. Our findings are consistent with growing evidence that dysregulation of endogenous opioids may have an important role in the pathophysiology of addictions.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies.

          There is a longstanding association between substance-use disorders (SUDs) and the psychological construct of impulsivity. In the first section of this review, personality and neurocognitive data pertaining to impulsivity will be summarised in regular users of four classes of substance: stimulants, opiates, alcohol and 3,4-methylenedioxymethamphetamine (MDMA). Impulsivity in these groups may arise via two alternative mechanisms, which are not mutually exclusive. By one account, impulsivity may occur as a consequence of chronic exposure to substances causing harmful effects on the brain. By the alternative account, impulsivity pre-dates SUDs and is associated with the vulnerability to addiction. We will review the evidence that impulsivity is associated with addiction vulnerability by considering three lines of evidence: (i) studies of groups at high-risk for development of SUDs; (ii) studies of pathological gamblers, where the harmful consequences of the addiction on brain structure are minimised, and (iii) genetic association studies linking impulsivity to genetic risk factors for addiction. Within each of these three lines of enquiry, there is accumulating evidence that impulsivity is a pre-existing vulnerability marker for SUDs.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Opioids excite dopamine neurons by hyperpolarization of local interneurons.

            Increased activity of dopamine-containing neurons in the ventral tegmental area is necessary for the reinforcing effects of opioids and other abused drugs. Intracellular recordings from these cells in slices of rat brain in vitro showed that opioids do not affect the principal (dopamine-containing) neurons but hyperpolarize secondary (GABA-containing) interneurons. Experiments with agonists and antagonists selective for opioid receptor subtypes indicated that the hyperpolarization of secondary cells involved the mu-receptor. Most principal cells showed spontaneous bicuculline-sensitive synaptic potentials when the extracellular potassium concentration was increased from 2.5 to 6.5 or 10.5 mM; these were prevented by TTX and assumed to result from action potentials arising in slightly depolarized local interneurons. The frequency of these synaptic potentials, but not their amplitudes, was reduced by opioids selective for mu-receptors. It is concluded that hyperpolarization of the interneurons by opioids reduces the spontaneous GABA-mediated synaptic input to the dopamine cells. In vivo, this would lead to excitation of the dopamine cells by disinhibition, which would be expected to contribute to the positive reinforcement seen with mu-receptor agonists such as morphine and heroin.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Integration of impulsivity and positive mood to predict risky behavior: development and validation of a measure of positive urgency.

              In 3 studies, the authors developed and began to validate a measure of the propensity to act rashly in response to positive affective states (positive urgency). In Study 1, they developed a content-valid 14-item scale, showed that the measure was unidimensional, and showed that positive urgency was distinct from impulsivity-like constructs identified in 2 models of impulsive behavior. In Study 2, they showed that positive urgency explained variance in risky behavior not explained by measures of other impulsivity-like constructs, differentially explained positive mood-based risky behavior, differentiated individuals at risk for problem gambling from those not at risk, and interacted with drinking motives and expectancies as predicted to explain problem drinking behavior. In Study 3, they confirmed the hypothesis that positive urgency differentiated alcoholics from both eating-disordered and control individuals. ((c) 2007 APA, all rights reserved).
                Bookmark

                Author and article information

                Journal
                Neuropsychopharmacology
                Neuropsychopharmacology
                Neuropsychopharmacology
                Nature Publishing Group
                0893-133X
                1740-634X
                June 2016
                10 November 2015
                09 December 2015
                1 June 2016
                : 41
                : 7
                : 1742-1750
                Affiliations
                [1 ]Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London , London, UK
                [2 ]Department of Psychobiology, Universidade Federal de São Paulo , São Paulo, Brazil
                [3 ]Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London , London, UK
                [4 ]Imanova Ltd., Centre for Imaging Sciences , London, UK
                [5 ]Department of Neuroimaging, Institute of Psychiatry, King's College , London, UK
                [6 ]Department of Imaging, Division of Experimental Medicine, Department of Medicine, Imperial College , London, UK
                [7 ]Drug Control Centre, Analytical and Environmental Sciences, King's College London , London, UK
                [8 ]National Problem Gambling Clinic, CNWL NHS Foundation Trust, Imperial College London , London, UK
                [9 ]Centre for Gambling Research, Department of Psychology, University of British Columbia Vancouver , Vancouver, Canada
                Author notes
                [* ]Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London , 160 Du Cane Road, London W12 0NN, UK, Tel: +004420 7594 7047, Fax: +004420 7594 6548, E-mail: anne.lingford-hughes@ 123456imperial.ac.uk
                Author information
                http://orcid.org/0000-0003-3612-6687
                Article
                npp2015340
                10.1038/npp.2015.340
                4869041
                26552847
                06ab8e4c-ce9b-4e88-b551-d6f475ace871
                Copyright © 2016 American College of Neuropsychopharmacology

                This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

                History
                : 29 June 2015
                : 08 October 2015
                : 09 October 2015
                Categories
                Original Article

                Pharmacology & Pharmaceutical medicine
                Pharmacology & Pharmaceutical medicine

                Comments

                Comment on this article